跳至主要内容
临床试验/NCT01182844
NCT01182844已完成不适用

Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota

Vanessa Stadlbauer-Koellner, MD2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2010年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
2
主要终点
Change of Neutrophil Phagocytosis From Baseline to 3 Months

研究概览

简要总结

Obesity and metabolic syndrome are linked by inflammation. Gut flora seems to play an important role in the development of inflammation and metabolic syndrome in obesity. Modulation of gut flora by probiotics has been shown in animal studies to positively influence inflammation and metabolic disturbances.

Lactobacillus casei Shirota is able to decrease metabolic endotoxemia by altering gut flora composition and gut permeability which leads to an improvement in neutrophil function and insulin resistance in obesity.

The aim of the current study is to investigate the effect of Lactobacillus casei Shirota supplementation over 12 weeks on neutrophil function (phagocytosis, oxidative burst and TLR expression) in patients with metabolic syndrome.

Furthermore the investigators aim to investigate the effect of Lactobacillus casei Shirota supplementation over 12 weeks on glucose tolerance, insulin resistance, inflammation, gut flora composition, gut permeability, and endotoxemia in metabolic syndrome

详细描述

Obesity and metabolic disorders (type 2 diabetes and insulin resistance) are tightly linked to inflammation. Obesity, a pandemic affecting 30-50% of the adult population, is mediated by a variety of genetic and environmental factors. It is well described that cytokines cause insulin resistance which causes hyperinsulinemia and excessive fat storage in adipose tissue and the liver. However, the triggering factor, linking inflammation to metabolic syndrome has not been fully elucidated yet.

Recently it has been hypothesized that the gut flora is an important factor in this vicious cycle of obesity, metabolic disease and inflammation. Firstly, metabolic activities of the gut microbiota facilitates the extraction of calories from ingested dietary substances and helps to store these calories in host adipose tissue for later use. Second, the gut bacterial flora of obese mice and humans include fewer Bacteroidetes and correspondingly more Firmicutes than that of their lean counterparts, suggesting that differences in caloric extraction of ingested food substances may be due to the composition of the gut microbiota. Furthermore, bacterial lipopolysaccharide derived from the intestinal microbiota may trigger inflammation, linking it to high-fat diet-induced metabolic syndrome. High-fat diet induces insulin resistance and oxidative stress in mice and is associated with increased gut permeability. high fat diet induces a low-grade endotoxemia in mice ("metabolic endotoxemia) and infusing endotoxin causes weight gain and insulin resistance. This has also been shown in humans, where patients with fatty liver had a susceptibility to higher gut permeability, possibly causing increased endotoxin levels.

Endotoxin and Lipopolysaccharide-binding protein (LBP) is elevated in obese patients, patients with type 2 diabetes and patients with liver steatosis. Endotoxin causes a significant increase in proinflammatory cytokine production in adipocytes via a TLR mediated pathway, contribution to the proinflammatory state in obesity. Endotoxin levels correlate with adiponectin and insulin suggesting a pathophysiological link between obesity, inflammation and metabolic disease.

As described above, endotoxin is related to increased inflammation and oxidative stress, causing insulin resistance. Adipocytes have been shown to play a dynamic role in regulation of inflammation by producing cytokines via a Toll-like receptor (TLR)/Nuclear Factor kappa B (NFkB) mediated pathway.But not only adipocytes are in a proinflammatory state - also circulating mononuclear cells have been described to be activated. Clinical evidence suggests immune dysfunction in obesity, since obese patients are more prone to infections after surgery, higher incidence of lower respiratory infection which is also underlined by impairment of cell-mediated immune responses in vivo and in vitro and a reduced intracellular killing by neutrophils.

A similar situation has been recently described in alcoholic cirrhosis and alcoholic hepatitis, which is also a proinflammatory condition with impaired innate immunity, leading to infection. Endotoxin has been described as a key mediator and inadequate activation of neutrophils leading to high oxidative burst and energy depletion of the cells with consecutive impaired phagocytic capacity has been described.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent
  • Fasting blood glucose >95mg/dL
  • Metabolic syndrome defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel-III (ATP-III) -ATPIII criteria (3 out of 5)
  • Abdominal obesity (waist circumference >102 in men or >88 in women)
  • Elevated blood pressure (>135/>85) or drug treatment for elevated blood pressure
  • Fasting blood glucose >100mg/dL or previously known type 2 diabetes mellitus,
  • High Density Lipoprotein (HDL) cholesterol <40 mg/dL (men) or <50 mg/dL (women) or drug treatment for low HDL cholesterol
  • Triglycerides >150 mg/dL or drug treatment for elevated for high triglycerides
  • HbA1C ≤7.0%

排除标准

  • Drug treatment for diabetes mellitus
  • Liver cirrhosis (biopsy proven) or elevated transaminases (>2x Upper Limit of Normla (ULN))
  • Inflammatory bowel disease (Crohns disease, ulcerative colitis)
  • Celiac disease
  • Alcohol abuse (more than 40g alcohol per day in the history)
  • Clinical evidence of active infection
  • Antibiotic treatment within 7 days prior to enrolment
  • Use of immunomodulating agents within previous month (steroids etc.)
  • Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the study
  • Any severe illness unrelated to metabolic syndrome
  • Malignancy
  • Pregnancy

结局指标

主要结局

Change of Neutrophil Phagocytosis From Baseline to 3 Months

时间窗: 3 months

The Phagotest® (Orpegen Pharma, Heidelberg, Germany) is used to measure phagocytosis by using Fluorescein isothiocyanate (FITC)-labelled opsonized E. coli bacteria.

Change of Burst (%) From Baseline to 3 Months

时间窗: 3 months

The Phagotest® (Orpegen Pharma, Heidelberg, Germany) is used to measure phagocytosis by using FITC-labelled opsonized E. coli bacteria. The Phagoburst® kit (Orpegen Pharma, Heidelberg, Germany) is used to determine the percentage of neutrophils that produce reactive oxidants with or without stimulation.

次要结局

  • Change in Indices of Glucose Tolerance and Insulin Resistance(3 months)
  • Change of Gut Permeability From Baseline to 3 Months(3 months)
  • Change in oxLDL (Oxidative Low Density Lipoprotein) From Baseline to 3 Months(3 months)
  • Change in Interleukin-6 (IL-6) From Baseline to 3 Months(3 months)
  • Change in Interleukin-10 (IL-10) From Baseline to 3 Months(3 months)

研究者

发起方
Vanessa Stadlbauer-Koellner, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Vanessa Stadlbauer-Koellner, MD

Associate Professor

Medical University of Graz

研究点 (2)

Loading locations...

相似试验